Light Horse Therapeutics, a San Diego, CA-based developer of small molecule therapeutics, raised $62M in Sequence A funding.
The spherical was led by Versant Ventures and included Mubadala Capital in addition to Bristol-Myers Squibb Co, Taiho Ventures, and AbbVie.
The corporate intends to make use of the funds to develop operations and its growth efforts.
Led by CEO Markus Renschler, Mild Horse has developed a proprietary platform that uncovers novel practical websites in disease-critical targets. The corporate built-in approaches to construct this precision genetic editing-based platform that interrogates proteins of their native setting, offering a greater discovery of scientific candidates.
Its expertise turns typical drug discovery on its head by first figuring out novel practical domains after which screening for chemistry. This function-first strategy is the converse of conventional screening-first methodologies.
The staff additionally consists of:
- Thomas Daniel, MD, Chairman
- Laure Escoubet, PhD, CSO
- Brian Liau, PhD, scientific co-founder
- Ben Cravatt, PhD, scientific co-founder
- Nathanael Grey, PhD, scientific co-founder
FinSMEs
10/01/2025
